Koru Medical Systems, Inc. (KRMD)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 704440 · fiscal year ends in Dec
Closing price $3.00 on 30 Oct 2026; 52-week range $2.93 to $6.52.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $45.1M
- Revenue growth
- 22.4%
- Net income, last twelve months
- -$1.8M
- Earnings per share
- $0.00
- Gross margin
- 62.4%
- Operating margin
- -3.7%
- Net margin
- -4.0%
- Free cash flow
- $776.7K
- Return on equity
- -10.1%
- Market value
- $138.2M
- Cash
- $8.3M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 46.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $41.1M | -$3.0M | -$2.6M | -$0.06 | -$470.1K | 10-K filed 12 Mar 2026 |
| FY2024 | 31 Dec 2024 | $33.6M | -$6.4M | -$6.1M | -$0.13 | -$1.6M | 10-K filed 12 Mar 2025 |
| FY2023 | 31 Dec 2023 | $28.5M | -$10.3M | -$13.7M | -$0.30 | -$5.7M | 10-K filed 13 Mar 2024 |
| FY2022 | 31 Dec 2022 | $27.9M | -$10.8M | -$8.7M | -$0.19 | -$8.2M | 10-K filed 8 Mar 2023 |
| FY2021 | 31 Dec 2021 | $23.5M | -$7.0M | -$4.6M | -$0.10 | -$4.7M | 10-K filed 2 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $12.0M | $252.4K | $0.01 |
| Q1 FY2026 | 31 Mar 2026 | $11.8M | -$807.1K | -$0.02 |
| Q4 FY2025 | 31 Dec 2025 | $10.9M | -$486.9K | -$0.01 |
| Q3 FY2025 | 30 Sep 2025 | $10.4M | -$778.0K | $0.02 |
| Q2 FY2025 | 30 Jun 2025 | $10.2M | -$206.9K | $0.00 |
| Q1 FY2025 | 31 Mar 2025 | $9.6M | -$1.2M | $0.03 |
| Q4 FY2024 | 31 Dec 2024 | $8.8M | -$1.6M | -$0.03 |
| Q3 FY2024 | 30 Sep 2024 | $8.2M | -$1.6M | -$0.03 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $30.2M | 73.5% |
| Non-US | $10.9M | 26.5% |
Company events
The newest 8-K filings of 133 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 14 Aug 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Jun 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 21 May 2026 | 8-K | Shareholder vote | 5.07 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Apr 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 16 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 12 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 11 Feb 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 25 Nov 2025 | 8-K | Material agreement | 1.01, 9.01 |
| 12 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 360 held.
| Filed | Form | Period |
|---|---|---|
| 14 Aug 2026 | 8-K | 13 Aug 2026 |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 30 Jun 2026 | 8-K | 24 Jun 2026 |
| 21 May 2026 | 8-K | 19 May 2026 |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 9 Apr 2026 | DEF 14A | 31 Dec 2025 |
| 3 Apr 2026 | 8-K | 30 Mar 2026 |
| 16 Mar 2026 | 8-K | 12 Mar 2026 |
| 12 Mar 2026 | 10-K | 31 Dec 2025 |
| 12 Mar 2026 | 8-K | 12 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 8 Sep 2026 | Kalbermatten Adam R, Chief Commercial Officer | Purchase | 32,000 | $3.16 | $101.1K | 394,017 | 9 Sep 2026 |
| 11 Jun 2026 | Kalbermatten Adam R, President-Chief Commercial Off | Purchase | 5,000 | $3.96 | $19.8K | 305,000 | 15 Jun 2026 |
| 11 Jun 2026 | Kalbermatten Adam R, President-Chief Commercial Off | Purchase | 7,500 | $3.93 | $29.5K | 312,500 | 15 Jun 2026 |
| 18 May 2026 | Schiller Eric, Chief Technology Officer | Purchase | 5,000 | $3.91 | $19.6K | 5,000 | 20 May 2026 |
| 15 May 2026 | Tharby Linda M, Chief Executive Officer | Purchase | 1,191 | $1191.00 | $1.4M | 620,622 | 20 May 2026 |
| 14 May 2026 | Pazdan Christopher, Chief Operating Officer | Purchase | 5,000 | $3.88 | $19.4K | 305,131 | 18 May 2026 |
| 14 May 2026 | Adams Thomas Edward, Chief Financial Officer | Purchase | 5,041 | $3.86 | $19.5K | 307,688 | 18 May 2026 |
| 14 May 2026 | Adams Thomas Edward, Chief Financial Officer | Purchase | 459 | $3.90 | $1.8K | 308,147 | 18 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 3 Aug 2026 | KALBERMATTEN ADAM R, Officer | 25,483 | $108.6K | 3 Aug 2026 |
| 14 May 2026 | Tharby Linda M, Officer | 7,326 | $28.9K | 14 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Jul 2026 | BlackRock, Inc. | 13G | 5.6% | 2.6M |
| 27 Apr 2026 | BlackRock, Inc. | 13G amended | 4.9% | 2.3M |
| 17 Feb 2026 | First Light Asset Management, LLC | 13G amended | 8.27% | 3.8M |
| 13 Feb 2026 | Topline Capital Management, LLC | 13G amended | 8.5% | 3.9M |
| 13 Feb 2026 | Horton Capital Partners Fund, LP | 13D amended | 12.62% | 5.8M |
| 21 Jan 2026 | BlackRock, Inc. | 13G | 5.1% | 2.3M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 888.4K | -2.09% | 4.04 |
| 30 Sep 2026 | 907.4K | -7.84% | 2.54 |
| 15 Sep 2026 | 984.6K | +11.32% | 5.78 |
| 31 Aug 2026 | 884.5K | +13.51% | 4.59 |
| 14 Aug 2026 | 779.3K | -2.69% | 2.13 |
| 31 Jul 2026 | 800.8K | -0.8% | 5.45 |
| 15 Jul 2026 | 807.2K | +18.97% | 8.22 |
| 30 Jun 2026 | 678.5K | -8.86% | 3.03 |
Funds that hold it
From each fund's latest Form 13F.
102 funds held it at 30 Jun 2026: 42 added and 24 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| First Light Asset Management, LLC | 3,387,902 | $14.2M | -380,478 |
| Topline Capital Management, LLC | 3,373,842 | $14.2M | -141,069 |
| BlackRock, Inc. | 2,628,352 | $11.0M | +256,526 |
| Vanguard Capital Management LLC | 1,818,121 | $7.6M | +131,897 |
| Geode Capital Management, LLC | 1,128,096 | $4.7M | +76,888 |
| Simcoe Capital LLC | 827,393 | $3.5M | +16,146 |
| Meros Investment Management, LP | 759,664 | $3.2M | -787 |
| Lionhunter Capital Management, LLC | 693,139 | $2.9M | – |
| State Street Corp. | 646,572 | $2.7M | -2,657 |
| Archon Capital Management LLC | 642,923 | $2.7M | 0 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B